WASHINGTON — Sen. Kamala Harris (D-Calif.) on Tuesday became the second leading Democratic primary candidate in as many days to unveil a comprehensive plan to lower drug prices.

Harris’s plan relies on government price-setting, allowing the federal government to cap price levels for drugs that are cheaper in other developed nations or whose prices increase by a rate exceeding inflation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Kill the goose that lays the golden eggs….who is going to innovate without the promise of profits? This is literally going to put the brakes on the current acceleration in the drug making space. Wonder why there is no innovation in antibiotics…no profit int it.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy